2015
Teaching Psychosocial Interventions for Opioid Use Disorder in Low and Middle Income Countries: Malaysia and China
Marienfeld C, Chawarski M. Teaching Psychosocial Interventions for Opioid Use Disorder in Low and Middle Income Countries: Malaysia and China. Academic Psychiatry 2015, 40: 507-513. PMID: 26626791, DOI: 10.1007/s40596-015-0438-2.Peer-Reviewed Original ResearchAripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
Wang G, Zhang Y, Zhang S, Chen H, Xu Z, Schottenfeld RS, Hao W, Chawarski MC. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. Journal Of Substance Use And Addiction Treatment 2015, 62: 84-88. PMID: 26733277, PMCID: PMC4724444, DOI: 10.1016/j.jsat.2015.11.009.Peer-Reviewed Original ResearchConceptsRisperidone-treated patientsSimpson-Angus ScaleVisual analog scalePsychotic symptomsRisperidone groupSelf-reported adverse effectsClinical Global Impressions-SeverityKaplan-Meier survival analysisAdverse effectsAripiprazole-treated patientsEfficacy of aripiprazoleMethamphetamine-Associated PsychosisExtra-pyramidal symptomsInpatient hospital stayTreatment of methamphetamineNegative Syndrome ScaleGreater methamphetamineHospital stayAripiprazole groupEntire studyAngus ScaleAnalog scaleAcute methamphetamineChinese patientsIllness ScaleEvaluation of an implementation of methadone maintenance treatment in China
Marienfeld C, Liu P, Wang X, Schottenfeld R, Zhou W, Chawarski MC. Evaluation of an implementation of methadone maintenance treatment in China. Drug And Alcohol Dependence 2015, 157: 60-67. PMID: 26601934, PMCID: PMC4663107, DOI: 10.1016/j.drugalcdep.2015.10.001.Peer-Reviewed Original ResearchConceptsInjection drug useMethadone maintenance treatmentMMT exposureDrug useMaintenance treatmentUrine testsPositive testOpiate positive urine testsDaily methadone dosesPositive urine testHigher adherence ratesOpioid use disorderNegative urine testsSelf-reported drug useElectronic medical recordsPriority improvement areasMonth drug useMethadone dosesMethadone dosingDose adjustmentAdherence ratesDaily dosesMedical recordsTreatment daysUse disordersExpanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN. Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 554-561. PMID: 25564105, PMCID: PMC4382671, DOI: 10.1097/qai.0000000000000510.Peer-Reviewed Original ResearchConceptsInjection-related risk behaviorsBUP/NXRisk behaviorsOpioid useNegative urinalysisTreatment strategiesInjection opioid useOpioid-dependent PWIDThrice-weekly dosingPrimary end pointBuprenorphine/naloxoneOpioid use disorderOpioid-dependent peopleEvidence-based treatmentsBehavioral drugBuprenorphine-naloxoneDose taperingOpioid injectionWeek 78HIV infectionActive treatmentHIV incidenceWeek 26Treatment optionsTreatment completionProfiles of psychiatric disorders among heroin dependent individuals in Changsha, China
Yang M, Liao Y, Wang Q, Chawarski MC, Hao W. Profiles of psychiatric disorders among heroin dependent individuals in Changsha, China. Drug And Alcohol Dependence 2015, 149: 272-279. PMID: 25680517, PMCID: PMC4609506, DOI: 10.1016/j.drugalcdep.2015.01.028.Peer-Reviewed Original ResearchConceptsHeroin-dependent individualsStructured Clinical InterviewMental health disordersSubstance use disordersLow socio-economic statusMood disordersAxis IDSM-IV-TR Axis II Personality DisordersUse disordersClinical InterviewHealth disordersSocio-economic statusDSM-IV-TR Axis IDSM-IV Axis IPersonality disorderDependent individualsAxis II personality disordersLifetime DSM-IV Axis IBorderline personality disorderDrug rehabilitation centersLifetime disordersPatient EditionPsychiatric disordersLifetime diagnosisRehabilitation settingsHepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China
Zhou W, Wang X, Zhou S, Xie N, Liu P, Luo L, Peng J, Liu M, Desrosiers A, Schottenfeld R, Chawarski MC. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015, 110: 796-802. PMID: 25529103, PMCID: PMC4598328, DOI: 10.1111/add.12836.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentInjection drug useHCV seroconversionPatients HCVSeroconversion ratesDrug useOpiate positive urine testsHepatitis C virus infectionRisk behaviorsMethadone maintenance treatment patientsMethadone maintenance treatment programHepatitis C seroconversionC virus infectionUrine toxicology resultsHepatitis C virusMaintenance treatment programPotential risk factorsOpiate-dependent individualsCross-sectional surveyHCV seroprevalenceMMT clinicsMaintenance treatmentTreatment patientsC virusUrine tests
2014
Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China
Zhang Y, Xu Z, Zhang S, Desrosiers A, Schottenfeld RS, Chawarski MC. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. Journal Of Psychiatric Research 2014, 53: 99-102. PMID: 24613031, PMCID: PMC4004368, DOI: 10.1016/j.jpsychires.2014.02.010.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePsychiatric symptomsAmphetamine-type stimulantsKetamine groupKetamine useAnxiety depressionInpatient psychiatry wardUrine toxicology screenProportion of participantsPsychiatric Rating ScaleLower scoresWard admissionToxicology screenClinical recordsPsychiatry wardInpatient treatmentHigher scoresPrimary drugATS useBPRS subscalesMajor drug problemStudy participantsKetamineSymptomsATS users
2012
Drug use in rural China: a preliminary investigation in Hunan Province
Deng Q, Tang Q, Schottenfeld RS, Hao W, Chawarski MC. Drug use in rural China: a preliminary investigation in Hunan Province. Addiction 2012, 107: 610-613. PMID: 21906200, PMCID: PMC4596718, DOI: 10.1111/j.1360-0443.2011.03648.x.Peer-Reviewed Original ResearchConceptsRural drug usersDrug usersDrug abusersDrug useHuman immunodeficiency virusDrug treatment participationSubstance abuse treatmentImmunodeficiency virusNeedle sharingLow prevalencePrimary drugRural areasDrug abuse patternsAbuse treatmentEarly onsetTreatment participationDrug abuseAbuse patternsTreatment pointsTreatment penetrationHigher proportionLower proportionAbusersAbuseSubstantial problem
2010
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial
Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug And Alcohol Dependence 2010, 115: 237-239. PMID: 21159452, PMCID: PMC3076517, DOI: 10.1016/j.drugalcdep.2010.09.024.Peer-Reviewed Original ResearchConceptsHIV risk reduction counselingMethadone maintenance treatmentRisk reduction counselingIllicit opiate useHIV risk behaviorsBehavioral drugReduction counselingClinical trialsOpiate useMMT servicesRisk behaviorsPrimary outcome measurePilot clinical trialTime of enrollmentSignificant baseline differencesHeroin-dependent individualsNegative test resultsMMT clinicsDaily medicationMaintenance treatmentMMT programBaseline differencesOutcome measuresMMT groupTreatment retention